|
Volumn 5, Issue 2, 2009, Pages 76-77
|
Imaging in osteoarthritis trials: Useful or just expensive?
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIINFLAMMATORY AGENT;
DISEASE MODIFYING ANTIOSTEOARTHRITIS DRUG;
LICOFELONE;
NAPROXEN;
RISEDRONIC ACID;
UNCLASSIFIED DRUG;
ARTICLE;
CLINICAL TRIAL;
COST EFFECTIVENESS ANALYSIS;
DIAGNOSTIC VALUE;
DISEASE COURSE;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG MECHANISM;
HUMAN;
INTERMETHOD COMPARISON;
JOINT CAVITY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OSTEOARTHRITIS;
OSTEOLYSIS;
PRIORITY JOURNAL;
QUANTITATIVE ANALYSIS;
RADIODIAGNOSIS;
RADIOGRAPHY;
RELIABILITY;
RISK FACTOR;
SENSITIVITY AND SPECIFICITY;
ANTIRHEUMATIC AGENTS;
DISEASE PROGRESSION;
HUMANS;
JOINTS;
MAGNETIC RESONANCE IMAGING, INTERVENTIONAL;
OSTEOARTHRITIS;
TREATMENT OUTCOME;
|
EID: 59849129885
PISSN: 17458382
EISSN: 17458390
Source Type: Journal
DOI: 10.1038/ncprheum0990 Document Type: Article |
Times cited : (1)
|
References (6)
|